NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization11.76 mln
Float8.57 mln
Earnings Date08/06/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
4.30
Transformational upside
Relative Strength
28
/ 100
Underperforming
Debt / Equity
0.00
Debt-free
ROE
-87.96
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Aprea Therapeutics is a Pennsylvania-based company working to bring new cancer treatments to patients. The company is currently testing two experimental drugs in early-stage clinical trials ? one targeting a protein called WEE1 and another targeting ATR ? both designed to fight solid tumors by disrupting the way cancer cells repair their DNA. Its approach focuses on exploiting specific weaknesses in cancer cells to slow or stop tumor growth.
